Immunovia Announces Collaboration With Mount Sinai Health System To Validate Early Detection Blood Test For Pancreatic Cancer
LUND, Sweden & NEW YORK--(BUSINESS WIRE)--Immunovia AB is pleased to announce that Mount Sinai Health System will be one of the first sites participating in a prospective clinical study for the early diagnosis of pancreatic cancer. Designed to validate Immunovia´s blood test, IMMray™ PanCan-d, the study will run for three years across sites in both the US and Europe, starting second half of 2016.